Clinical trial · no report yet · Phase 3
ARIAN
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
- NCT06431633 ↗
- Recruiting
- Fundación GECP
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Clinical Trial of Adjuvant Treatment With Sacituzumab and Zimberelimab for Stage IB-IIIA-IIIB(N2) Previously Resected (R0) Non-small Cell Lung Cancer Patients That Did Not Achieve Pathological Complete Response After Neoadjuvant treatment_ARIAN
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Lung Diseases; Carcinoma, Non-Small-Cell Lung; Resectable Lung Non-Small Cell Carcinoma
- Interventions
- Zimberelimab; Sacituzumab govitecan; Cisplatin; Carboplatin
- Arms
- ARM 1: Observation-investigator decision · Active comparator
- ARM 2: Immunotherapy. Zimberelimab treatment for 13 cycles · Experimental
- ARM 3: Sacituzumab Govitecan + Zimberelimab for 8 cycles + Zimberelimab for 5 cycles · Experimental
- Enrollment
- 129 (estimated)
- Primary outcomes
- Disease free survival
- Sponsor
- Fundación GECP
- Start
- Feb 4, 2025
- Primary completion
- Nov 30, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT06431633 · updated May 18, 2026